Indication
MAP Kinase Family Gene Mutation
2 clinical trials
2 products
1 drug
Clinical trial
A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway AberrationsStatus: Recruiting, Estimated PCD: 2025-07-31
Product
PimasertibProduct
TovorafenibClinical trial
A Multi-Center Phase I Dose Escalation Study of Avutometinib, a RAF/MEK Clamp, in Pediatric Patients With Refractory or Recurrent Solid Tumors Harboring Activating MAPK Pathway AlterationsStatus: Recruiting, Estimated PCD: 2029-10-20
Drug
Avutometinib